Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?

Core Insights - Haemonetics Corporation's Hospital business recovery is expected to drive growth in upcoming quarters, with strong adoption of the NexSys PCS system indicating long-term potential [1][9] - The company has a market capitalization of $2.82 billion and has consistently beaten earnings estimates over the past four quarters, with an average surprise of 6.8% [2] Haemonetics' Key Upsides - The NexSys PCS system, which is FDA-cleared, enhances plasma yield collections and improves productivity, resulting in a 16-minute reduction in donor door-to-door time on average [3] - The introduction of proprietary Persona Technology strengthens the NexSys PCS value proposition, contributing to margin expansion in Q3 FY26 [4] - The Hospital business is well-positioned for growth, with a 2% organic revenue increase through December 2025, driven by an 11% growth in Blood Management Technologies [5][6] Concerns for Haemonetics - The company has a long-term debt of $920 million and a debt-to-capital ratio of 50.2%, indicating solvency concerns [9][10] - Haemonetics operates in a highly competitive environment, which may impact revenue and profit if product adoption is slower than expected [11] - The Zacks Consensus Estimate for fiscal 2026 earnings remains at $4.95 per share, with revenues projected at $1.33 billion, reflecting a 2.6% decrease from the previous year [12]